Skip to content
Renca Mouse Model
According to the American Cancer Society, there are over 300,000 new cases of kidney cancer, and 13,000 deaths worldwide each year. Kidney cancer is one of the 10 most common cancers in the United States with the most common being renal cell carcinoma which accounts for roughly 90% of kidney cancers.
We have characterized a syngeneic mouse model for renal cell carcinoma using the Renca cell line expressed as a flank model (subcutaneous implantation) in BALB/c mice. Our model can be used for the study of primary tumors and late-stage metastatic disease in immunocompetent mice.
Immunotherapies and therapy-driven immune responses
Our model uses immunocompetent mice providing a valuable environment to study immune cell infiltration, cytokine responses and effectiveness of immunotherapies.
Fast Growing and Reproducible
Our Renca syngeneic model allows for efficient and reproducible analysis of novel treatments.
Metastatic Potential
Renca cells have been shown to metastasize to other organs, including the lungs and lymph nodes, making it a valuable model for studying kidney cancer metastasis.
Renca Murine Renal Cell Carcinoma
Our Renca syngeneic model is highly aggressive renal cancer line that is valuable for the evaluation of novel treatments.
Commonly Requested Endpoints
Histopathology
Our customizable histopathological analysis can help evaluate tumor microenvironments, track tumor progression and metastases and inform treatment decisions.
Flow Cytometry
Our flow cytometry expertise can help characterize tumor-infiltration T lymphocytes, identity immune biomarkers, and so much more.